BioCentury | Aug 18, 2014
Strategy

Afrezza, partnered

...from the drug for MannKind to get the remaining $575 million. Analysts Christopher James of Brinson Patrick...
BioCentury | Apr 28, 2014
Analyst Picks & Changes

Analyst picks & changes

...& changes Company Bank Analyst Coverage Opinion Wk chg 4/25 cls BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Brinson Patrick...
BioCentury | Jul 29, 2013
Finance

Analyst tracks

...Analyst tracks Christopher James joined boutique investment bank Brinson Patrick Securities Corp. as a senior analyst focused...
BioCentury | May 20, 2013
Analyst Picks & Changes

Analyst picks & changes

...raised his target to $54 from $44 on the Elan deal. Titan Pharmaceuticals Inc. (OTCBB:TTNP) Brinson Patrick...
BioCentury | Sep 10, 2012
Finance

Banker tracks

...Banker tracks Vernon Bernardino joined boutique investment bank Brinson Patrick Securities Corp. as a senior research analyst...
BioCentury | Jul 23, 2012
Finance

Banker tracks

...Banker tracks Kevin Tyler joined boutique investment bank Brinson Patrick Securities Corp. as managing director of healthcare...
BioCentury | May 25, 2012
Financial News

Life sciences visits the ATM

...record $90 million through at-the-market (ATM) offerings in 1Q12, according to data from ATM specialist Brinson Patrick...
BioCentury | May 7, 2012
Finance

Into the darkness

...the larger trend seems to be toward greater usage of the financing vehicle. According to Brinson Patrick...
...firms and will most likely trade public shares for them first." Companies and Institutions Mentioned Brinson Patrick...
BioCentury | Jan 9, 2012
Finance

Venture tracks

...at Genzyme Corp. , a subsidiary of Sanofi (Euronext:SAN; NYSE:SNY). Banker tracks Michael Higgins joined Brinson Patrick...
BioCentury | Jan 2, 2012
Finance

Living creatively

...this year. Companies generally pay a 3-5% fee for ATMs. By comparison, Todd Wyche of Brinson Patrick...
Items per page:
1 - 10 of 12
BioCentury | Aug 18, 2014
Strategy

Afrezza, partnered

...from the drug for MannKind to get the remaining $575 million. Analysts Christopher James of Brinson Patrick...
BioCentury | Apr 28, 2014
Analyst Picks & Changes

Analyst picks & changes

...& changes Company Bank Analyst Coverage Opinion Wk chg 4/25 cls BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Brinson Patrick...
BioCentury | Jul 29, 2013
Finance

Analyst tracks

...Analyst tracks Christopher James joined boutique investment bank Brinson Patrick Securities Corp. as a senior analyst focused...
BioCentury | May 20, 2013
Analyst Picks & Changes

Analyst picks & changes

...raised his target to $54 from $44 on the Elan deal. Titan Pharmaceuticals Inc. (OTCBB:TTNP) Brinson Patrick...
BioCentury | Sep 10, 2012
Finance

Banker tracks

...Banker tracks Vernon Bernardino joined boutique investment bank Brinson Patrick Securities Corp. as a senior research analyst...
BioCentury | Jul 23, 2012
Finance

Banker tracks

...Banker tracks Kevin Tyler joined boutique investment bank Brinson Patrick Securities Corp. as managing director of healthcare...
BioCentury | May 25, 2012
Financial News

Life sciences visits the ATM

...record $90 million through at-the-market (ATM) offerings in 1Q12, according to data from ATM specialist Brinson Patrick...
BioCentury | May 7, 2012
Finance

Into the darkness

...the larger trend seems to be toward greater usage of the financing vehicle. According to Brinson Patrick...
...firms and will most likely trade public shares for them first." Companies and Institutions Mentioned Brinson Patrick...
BioCentury | Jan 9, 2012
Finance

Venture tracks

...at Genzyme Corp. , a subsidiary of Sanofi (Euronext:SAN; NYSE:SNY). Banker tracks Michael Higgins joined Brinson Patrick...
BioCentury | Jan 2, 2012
Finance

Living creatively

...this year. Companies generally pay a 3-5% fee for ATMs. By comparison, Todd Wyche of Brinson Patrick...
Items per page:
1 - 10 of 12